Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

IL-17A Neutralization Prevents Immune Checkpoint Inhibitor-Associated Myocarditis and Synergistically Enhances Immune Checkpoint Blockade Therapy

ABSTRACT: Immune checkpoint inhibitor (ICI)-associated myocarditis is a severe and often fatal immune-related adverse event observed in cancer immunotherapy. To investigate its pathogenesis and prevention, we performed spatial transcriptomics on cardiac tissue from mice treated with dual ICIs (anti–PD-1 and anti–CTLA-4) with or without IL-17A neutralizing antibody. Our analysis revealed immune-mediated fibrotic remodeling and distinct spatial immune cell distributions, providing insights into how IL-17A blockade mitigates cardiac toxicity without compromising immune activation.

ORGANISM(S): Mus musculus

PROVIDER: GSE297745 | GEO | 2026/04/28

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

IL-17A Neutralization Prevents Immune Checkpoint Inhibitor-Associated Myocarditis and Synergistically Enhances Immune Checkpoint Blockade Therapy

Project description:IL-17A Neutralization Prevents Immune Checkpoint Inhibitor-Associated Myocarditis and Synergistically Enhances Immune Checkpoint Blockade Therapy

| PRJNA1266108 | ENA

Clonal CD8 T cells orchestrate arrhythmogenic inflammation in immune checkpoint inhibitor-associated myocarditis

Project description:Objective: Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy but are frequently associated with immune-related adverse events, particularly in combination regimens. ICI-associated myocarditis (ICI-M) is rare but highly lethal, with a mortality rate approaching 50% and a notable risk of fatal ventricular arrhythmias. Prevention and effective management of ICI-M remain significant clinical challenges. This study aims to elucidate the immune landscape and spatial organization of immune cells in ICI-M using single-cell multi-omics in a preclinical mouse model. Methods: We utilized Ctla4+/–Pdcd1–/– mice, modeling human ICI-induced myocarditis. Single-cell RNA (scRNAseq) and T cell receptor (TCR) sequencing were performed on heart-infiltrating immune cells and peripheral blood mononuclear cells (PBMCs). Spatial transcriptomics was applied to map immune infiltration in cardiac tissue. Results: Approximately half of Ctla4+/–Pdcd1–/– mice died after 100 days, while Ctla4+/+ mice showed normal survival. ECG monitoring identified ventricular arrhythmias in 15% of Ctla4+/–Pdcd1–/– mice. Histology revealed severe myocardial inflammation and fibrosis. Cardiac scRNAseq data indicated that T cells were the predominant immune population in ICI-M hearts. TCR sequencing demonstrated substantial overlap in TCR clonotypes between cardiac-infiltrating and circulating CD8+ T cells. These TCR-shared CD8+ T cells exhibited an activated phenotype and were enriched in pathways associated with allograft rejection and inflammation. Spatial mapping revealed localization near the AV node and subendocardium, implicating potential CD8+ T cell–mediated conduction disruption. Conclusion: Clonal, activated CD8+ T cells contribute to arrhythmogenic myocarditis in ICI-M. Targeting specific TCR-peptide-MHC interactions may enable myocarditis prevention without impairing antitumor efficacy.

2025-06-11 | GSE299032 | GEO

Clonal CD8 T cells orchestrate arrhythmogenic inflammation in immune checkpoint inhibitor-associated myocarditis

2025-06-11 | GSE298932 | GEO

Cardiac tertiary immune niches drive immune activation in immune checkpoint inhibitor myocarditis

Project description:Using integrated spatial and single-cell analyses in a pharmacological murine model, we identified regional infiltration of inflammatory myeloid cells and PD-1⁺CD8⁺ T cells in the heart that organize into fibroblast-rich immune structures, which we term Tertiary T Cell Niches (TTCNs). TTCNs serve as hubs for T cell activation, sharing features of tertiary lymphoid structures. Complementary TCR analyses revealed clonal expansion of cardiac T cells following ICI treatment. Together, these findings suggest that cardiac tertiary immune structures play a central role in activating and recruiting immune cells in ICI myocarditis and highlight pathways that could mitigate ICI cardiotoxicity.

2026-04-06 | GSE327152 | GEO

Cardiac tertiary immune niches drive immune activation in immune checkpoint inhibitor myocarditis [CosMx]

2026-04-06 | GSE326904 | GEO

Comparative cardiac transcriptomics of immune checkpoint inhibitor induced myocarditis

Project description:Immune checkpoint inhibitors (ICIs) are improving cancer treatments strikingly. The raising use leads to the augmented occurrence of immune related events. Myocarditis is a rare, but severe form of these adverse events. Nine patients with proven ICI induced myocarditis were subjected to myocardial biopsy. The tissue was used for RNA-seq analyses.

2020-11-01 | E-MTAB-8867 | biostudies-arrayexpress

TRIM21 Enhances IL-17A Signaling and Drives Autoimmune Myocarditis by Promoting TRAF3 Lysosomal Degradation in Cardiac Fibroblasts

Project description:Myocarditis is a major health concern worldwide, often progressing to dilated cardiomyopathy (DCM) and sudden death, particularly in young individuals. However, the mechanisms driving the transition from acute myocarditis to inflammatory DCM (DCMi) remain unclear. Autoimmune responses, especially those involving interleukin (IL)-17A signaling, have been implicated, though the specific cellular targets and upstream regulators in the cardiac environment are not well understood. Here, we identify TRIM21, an E3 ubiquitin ligase, as a key regulator in this process. Using the experimental autoimmune myocarditis (EAM) model, we show that TRIM21 expression is significantly upregulated in cardiac fibroblasts (CFs) during DCMi and upon IL-17A stimulation. Surprisingly, TRIM21 deficiency attenuated EAM progression, reducing inflammatory neutrophils and Ly6Chigh monocytes/macrophages infiltration. Bone marrow chimeric and IL-17A neutralization experiments confirmed TRIM21's role in CFs, where it promotes IL-17A signaling by facilitating TRAF3 degradation via K27-linked polyubiquitination. These findings identify TRIM21 as a new target in CFs and uncover a regulatory mechanism for IL-17A signaling, suggesting that therapies targeting TRIM21 may need to be adapted to different microenvironments.

2025-11-14 | GSE281873 | GEO

Hormonal Therapies Upregulate MANF and Overcome Female Susceptibility to Immune Checkpoint Inhibitor-Myocarditis

Project description:Immune checkpoint inhibitors (ICIs) have been increasingly used in combination for cancer treatment, but are particularly associated with myocarditis. Here, we report that tumor-bearing mice exhibited response to treatment with combinatorial anti-PD-1 (programmed cell death 1) and anti-CTLA-4 (Cytotoxic T-lymphocyte Antigen-4) antibodies but also presented with cardiovascular toxicities observed clinically with ICI therapy, including myocarditis and arrhythmia. Female mice were preferentially affected with myocarditis compared to male mice, consistent with a previously described genetic model of ICI-myocarditis as well as emerging clinical data. Mechanistically, myocardial tissue from ICI-treated mice, the genetic mouse model, and human heart tissue from affected patients with ICI-myocarditis all exhibited downregulation of MANF (Mesencephalic Astrocyte Derived Neurotrophic Factor) and HSPA5 (Heat Shock 70kDa Protein 5) in the heart; this downregulation was particularly striking in female mice. ICI-myocarditis was amplified by heart-specific genetic deletion of mouse Manf and was attenuated by administration of recombinant MANF protein, suggesting a causal role. Ironically, both MANF and HSPA5 were transcriptionally induced by liganded estrogen receptor-βbeta and inhibited by androgen receptor. However, ICI treatment reduced serum estradiol concentration to a greater extent in female compared to male mice. Treatment with an estrogen receptor β-specific agonist as well as androgen depletion therapy attenuated ICI-associated cardiac effects. Taken together, our data suggest that ICI treatment inhibits the estradiol-dependent expression of MANF/HSPA5 in the heart, curtailing the cardiomyocyte response to immune injury. This endocrine-cardiac-immune pathway offers new insights into the mechanisms of sex differences in cardiac disease and may offer treatment strategies for ICI-myocarditis.

2022-09-18 | GSE213468 | GEO

Cardiac tertiary immune niches drive immune activation in immune checkpoint inhibitor myocarditis

Project description:Cardiac tertiary immune niches drive immune activation in immune checkpoint inhibitor myocarditis

| PRJNA1449525 | ENA

Immune checkpoint inhibitor–induced myocarditis is dependent on CD8 T cell–derived TNF and TNFR2 signaling

Project description:Immune checkpoint inhibition (ICI) has significantly advanced cancer treatment but is associated with immune-related adverse outcomes including lethal myocarditis. T cells against select cardiac antigens have emerged as a cause of myocarditis, yet the mechanisms by which these cells exert pathological effects remain unclear. To investigate the pathogenesis of ICI-induced myocarditis, we developed a mouse model with cardiac-restricted expression of the model antigen ovalbumin (Ova). Immunotherapy with antibodies against cytotoxic T cell antigen-4 (αCTLA-4) and programmed death-1 (αPD-1) uniquely drove the expansion of transferred Ova-specific naïve CD8 T cells and infiltration in the heart. The goal of this study was to identify pathways induced in immune cells interacting with pathogenic T cells. Here, Ova-specific CD8 T cells initiated innate immune activation, resulting in arrhythmias and lethal cardiomyopathy. The innate inflammation and cardiac damage were largely driven by T cell-derived tumor necrosis factor (TNF), as shown by the marked reduction of myocarditis in mice receiving TNF-deficient Ova-specific CD8 T cells or treated with tumor necrosis factor receptor 2 (TNFR2)-blocking antibody. Furthermore, targeting T cell-mediated innate inflammation via the TNF:TNFR2 axis ameliorated myocarditis while preserving the antitumor efficacy of immune checkpoint inhibitor (ICI) therapy. These findings clarify roles for the inhibitory receptors PD-1 and CTLA-4 in regulating self-reactive T cells and offer a clinically actionable path for protection from ICI-induced myocarditis while maintaining antitumor immunity.

2026-02-03 | GSE302512 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data